Keros Therapeutics (KROS) EBITDA (2019 - 2026)

Keros Therapeutics (KROS) has reported EBITDA for 8 consecutive years, with -$30.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 22.3% year-over-year to -$30.9 million; the trailing twelve-month figure through Jun 2026 stood at -$115.4 million (down 37089.74% YoY), and the FY2025 full-year result was $67.6 million, up 132.05% from the prior year.
• EBITDA eased to -$30.9 million in Q2 2026 per KROS's latest filing, from -$29.3 million in the prior quarter.
• Across five years, EBITDA topped out at $152.0 million in Q1 2025 and bottomed at -$58.7 million in Q3 2024.
• Historically, EBITDA has averaged -$27.0 million across 5 years, with a median of -$38.9 million in 2023.
• The sharpest annual moves came in 2022 and 2025: EBITDA slumped 556.8% in 2022, then soared 413.59% in 2025.
• Over 5 years, EBITDA stood at -$32.0 million in 2022, then plunged by 45.35% to -$46.5 million in 2023, then slipped by 14.64% to -$53.3 million in 2024, then surged by 45.04% to -$29.3 million in 2025, then retreated by 5.7% to -$30.9 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$30.9 million, -$29.3 million, and -$15.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.